The myth that a policy headline settles permission

A headline may use a short word such as allowed where the underlying document sets out something narrower. Begin by asking what kind of document is being cited. Is it a drug approval, a rule, an advisory vote or a statement about when the agency plans to act over broken rules? Keep that account attached to the claim. It helps prevent a change in one part of the record from becoming a finding about every part.

FDA is short for the Food and Drug Administration.

A draft from HHS dated October 30, 2026 addresses compounding for named patients. The Department of Health and Human Services is shortened to HHS here. The notice calls the policy nonbinding: a statement of intent that grants no right to compound. It is not FDA approval and does not change the formal list of raw ingredients. It says when HHS does not plan to act on compounding violations, with conditions attached.

What the draft sets out

The draft dated October 30, 2026 names BPC-157 with semax and KPV. Its other named peptides are MOTS-c, TB-500 and epitalon. For drugs made from these, HHS describes when it does not plan to take action against state-licensed pharmacies and doctors. The work must be for a person’s prescription and meet the draft’s conditions. The appendices limit the exact ingredients and routes. This is not open-ended permission.

Only single-ingredient drugs fit the draft; blends do not. It does not cover 503B outsourcing facilities. Those sites register with FDA and make sterile medicines in batches; sterile means no living germs. None of the named peptides is on the formal 503A bulks list of allowed raw drug ingredients, as checked November 3, 2026. The 503A route concerns work for a named patient. The draft gives no right to compound.

The committee account is now part of the record

In its account of the July 2026 review, HHS reports that six peptides received favorable votes from the committee; the review concerned seven peptides. That official account is in the draft’s appendices dated October 30, 2026. It is not FDA meeting minutes or a roll-call record. No vote totals are given. There is now an official account, with those limits.

The ingredient list does not change merely because a committee gives advice. FDA uses a formal process that includes public comment to change that list, as checked November 3, 2026. The agency’s framework keeps committee advice separate from a final rule. Agreement in a meeting and product approval remain distinct events.

Withdrawal is a separate event

On its bulk-substance page dated April 22, 2026, FDA groups BPC-157 and other substances under withdrawn nominations. A nomination is a request to add a substance to a list. The people who made these requests took them back. The table keeps FDA’s safety concerns. It gives no move date for each entry. Withdrawal is not clearance or approval.

Read a claim about withdrawal as a claim about a request. Then ask separately about drug approval and when the agency plans to act on rule violations. There is no need to combine those events into a single yes or no label.

Bring the remaining question to the prescriber

Ask which drug and route are planned, which conditions the prescriber sees as relevant, and how state obligations are addressed. The South Carolina medical board’s peptide notice, read November 3, 2026, still addresses research-grade peptides, made for lab work, and FDA-ineligible peptides, which fail federal eligibility rules. Ask the prescriber how the board’s notice applies alongside the federal draft. These documents do different jobs.